STAT+: Scientists test tetanus bacteria as a weapon to target pancreatic tumors
Pancreatic cancer has proved one of the most deadly forms of the disease, and the…
Category: biotechnology
.jpg)
STAT+: Al Sandrock, former top scientist at Biogen, named CEO at Voyager Therapeutics
Al Sandrock, the top scientist at Biogen who exited last year in a dispute over…
STAT+: An ALS therapy sets up a crucial test of the FDA’s independence
WASHINGTON — A high-profile, experimental therapy for ALS is teeing up a crucial test of…
STAT+: What makes a biotech a biotech?
The prototypical biotech company is easy to envision: think Moderna, Alnylam, and Genentech. But what…
STAT+: Illumina sues Guardant Health, saying former employees stole trade secrets to launch liquid biopsy firm
DNA sequencing giant Illumina is suing Guardant Health, a firm that has become both its…
Listen: Doing biotech in Ukraine, drug pricing déjà vu, & Covid surges overseas
How should pharma treat Russia? Why can’t Congress pass a drug pricing bill? And what…
STAT+: Alnylam sues Pfizer and Moderna for patent infringement in development of Covid-19 vaccines
Alnylam Pharmaceuticals has filed separate lawsuits alleging that Pfizer and Moderna infringed its patents in…
STAT+: Biogen publishes data on its Alzheimer’s drug in a little-known journal
When it comes to Biogen’s controversial Alzheimer’s drug Aduhelm, even publishing the data is steeped…
STAT+: Armed with heaps of cash and a veteran team, an upstart looks to disrupt DNA sequencing
SAN DIEGO — After quietly raising hundreds of millions of dollars and building a team…
STAT+: Combination treatment from Nektar and Bristol Myers Squibb fails to benefit patients with melanoma, study shows
Nektar Therapeutics said Monday that its experimental immunotherapy failed to provide additional benefit for patients…
He was creating the building blocks for drug developers worldwide. Then Russia started to bomb Kyiv
It was just last month, with the Covid-19 situation having calmed down in Kyiv, that…
STAT+: What to know about Amylyx’s ALS drug and a highly anticipated advisory panel meeting
Amylyx Pharmaceuticals is one heck of an encore. On March 30, the Food and Drug…
Listen: Gilead’s growing pains, Covid’s origins, & Theranos as prestige TV
Can biotech companies age gracefully? Where did Covid-19 come from? And does Theranos make for…
STAT+: Gilead’s Dan O’Day is pharma’s most charming executive — but with his deals falling apart, charm may not be enough
The news Gilead Sciences dropped Monday was so disappointing it irked even the nicest guy…
STAT+: Key Democrat moves to crack down on FDA accelerated approvals
WASHINGTON – A powerful Democratic lawmaker has introduced a bill that would dramatically rein in…
STAT+: Few public biotech companies disclose environmental, social, and governance steps
Environmental, social, and governance issues are gaining greater attention among investors, but only 30% of…
STAT+: A key study of Gilead’s breast cancer drug meets goal, but withheld data raise doubts
Gilead Sciences said Monday that a large clinical trial of its drug Trodelvy achieved its…
STAT+: With cash running short, Bluebird Bio and its gene therapies face uncertain future
Bluebird Bio, the troubled developer of gene therapies, has warned that cash is running short,…
‘Something is off here’: Black biotech entrepreneurs still struggle for funding as the industry pledges to diversify
SAN DIEGO — Paul Mola tried his best to keep cool. But inside, he was…
STAT+: With Aduhelm in limbo, Biogen starts laying off employees
Biogen’s largest-ever corporate restructuring began Wednesday, as employees around the world got word they would…
STAT+: Awaiting ‘definitive’ Alzheimer’s drug data, Roche and Genentech launch ambitious new study
Partners Roche and Genentech are studying whether their investigational treatment for Alzheimer’s disease can prevent…
STAT+: Aurinia Pharma’s takeout hopes dim with new legal challenge to key drug patent
Takeover speculation has swirled around Aurinia Pharmaceuticals since late 2019 when its lead drug, Lupkyni,…
STAT+: Vesalius Therapeutics launches to develop treatments for common diseases
Flagship Pioneering, the Cambridge, Mass., life sciences investment firm that helped found Moderna over a…
STAT+: 3 burning questions spurred by the big CRISPR patent ruling
On Monday, the U.S. Patent and Trademark Office ruled that CRISPR patents key to developing…
STAT+: UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies
Ending the latest chapter in a years-long legal battle over who invented CRISPR, the U.S….
.jpg)
STAT+: Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Intellia Therapeutics said Monday that its CRISPR-based therapy for a genetic nerve disorder reduced the…
Opinion: STAT+: What biotech can learn from past stock market downturns
“Dumpster fire.” “Biotech bear market.” “A market rout.” Going by recent descriptions of the performance of…
STAT+: With new trial data coming on Monday, Intellia CEO talks up the future of in vivo gene editing
In 1996, 32,655 Americans died from AIDS. A year later, that number was 16,685. The…
STAT+: Unraveling of Amicus spinout spells more trouble for gene therapy field
The abrupt dissolution of a blank-check merger on Thursday points to more trouble for the…
Listen: Biotech in 2022, the Omicron surge, & the Elizabeth Holmes verdict
How worrisome is Omicron? Are the vibes off in biotech? And does the Theranos verdict…
STAT+: Blueprint Medicines seeks ‘continuity, not change’ in CEO transition
For Jeff Albers, the decision to step down as the CEO of Blueprint Medicines after…
STAT+: Applied Therapeutics tried to muzzle short sellers — but the truth still came out
When short sellers began raising questions about New York-based Applied Therapeutics’ treatment for a rare…
STAT+: Texas is trying to create the next research triangle for biotech. Will it work?
Do you live in a city vying to be the country’s next biotech hub? Get…
STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch
Happy New Year! Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events,…
STAT+: 3 biotech trends to watch in 2022
It’s been a weird year for biotech stocks. One major index peaked in February, but…
STAT+: In a ‘baffling’ disappointment, BridgeBio’s heart drug misses primary goal in pivotal study
A treatment developed by BridgeBio for an increasingly common heart disease missed its primary endpoint…
STAT+: 7 challenges that could make or break Biogen’s 2022
Can Biogen pull itself back from the brink? The company is ending 2021 with dismal…
STAT+: 4 epilepsy-focused biotech companies to watch
More companies than ever before are training their sights on developing treatments for epilepsy, which…
STAT+: Worst biopharma CEO of 2021? There are too many to choose just one
I’m not naming the Worst Biopharma CEO for 2021. I chose 10. It’s been that…
STAT+: It’s the cardiovascular version of Alzheimer’s — and, for a biotech with a promising drug, it could be a windfall
Surprise diagnoses have a way of making Ph.D. candidates out of everyday people. Walter Feigenson’s…
Biogen slashes price of Alzheimer’s drug Aduhelm in half, plans $500M in cost-cutting
Biogen said Monday that it has reduced the price of its Alzheimer’s drug Aduhelm by…
STAT+: AbbVie asks the U.S. International Trade Commission to investigate Alvotech’s plans for a biosimilar Humira
In its latest bid to defend its franchise product, AbbVie (ABBV) has filed a complaint…
Listen: Covid in 2022, J.P. Morgan bows to pressure, & the year in review
Will we be getting boosters forever? Does Jamie Dimon hate Zoom? And how do you…
As Aduhelm faces doubts, Biogen plans another pivotal trial for 2022
Biogen said Thursday that it expects to begin a large clinical trial next May to…
Bowing to pressure, J.P. Morgan says its health care conference will be virtual
The J.P. Morgan Healthcare Conference, biotech’s biggest annual conference, will be virtual, the bank said…
STAT+: Biotech investor Eli Casdin on biotech’s bad December
Biotech investors are having some not-so-happy holidays. In the last few months, several major funds…
STAT+: Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Some of the biggest names in biotechnology, including Amgen, Moderna, and Sarepta Therapeutics, have pulled…
STAT+: More potent version of Global Blood sickle-cell drug improves hemoglobin response in small study
Global Blood Therapeutics said Monday that an experimental treatment for sickle cell disease nearly doubled…
STAT+: In a do-over study, Bellus Health cough treatment shows positive results
Results released Monday from a Phase 2 study of a chronic cough treatment being developed…
STAT+: J&J’s new CAR-T therapy shows long-term success, data show
By the time patients with multiple myeloma have gone through four or five different therapies,…